Workforce participation in relation to cancer diagnosis, type and stage: Australian population-based study of 163,556 middle-aged people.
Cancer diagnosis
Cancer type
Clinical characteristics
Cohort studies
Workforce participation
Journal
Journal of cancer survivorship : research and practice
ISSN: 1932-2267
Titre abrégé: J Cancer Surviv
Pays: United States
ID NLM: 101307557
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
12
10
2020
accepted:
07
04
2021
pubmed:
20
5
2021
medline:
12
4
2022
entrez:
19
5
2021
Statut:
ppublish
Résumé
To quantify the relationship of cancer diagnosis to workforce participation in Australia, according to cancer type, clinical features and personal characteristics. Questionnaire data (2006-2009) from participants aged 45-64 years (n=163,556) from the population-based 45 and Up Study (n=267,153) in New South Wales, Australia, were linked to cancer registrations to ascertain cancer diagnoses up to enrolment. Modified Poisson regression estimated age- and sex-adjusted prevalence ratios (PRs) for non-participation in the paid workforce-in participants with cancer (n=8,333) versus without (n=155,223), for 13 cancer types. Overall, 42% of cancer survivors and 29% of people without cancer were out of the workforce (PR=1.18; 95%CI=1.15-1.21). Workforce non-participation varied substantively by cancer type, being greatest for multiple myeloma (1.83; 1.53-2.18), oesophageal (1.70; 1.13-2.58) and lung cancer (1.68; 1.45-1.93) and moderate for colorectal (1.23; 1.15-1.33), breast (1.11; 1.06-1.16) and prostate cancer (1.06; 0.99-1.13). Long-term survivors, 5 or more years post-diagnosis, had 12% (7-16%) greater non-participation than people without cancer, and non-participation was greater with recent diagnosis, treatment or advanced stage. Physical disability contributed substantively to reduced workforce participation, regardless of cancer diagnosis. Cancer survivors aged 45-64 continue to participate in the workforce. However, participation is lower than in people without cancer, varying by cancer type, and is reduced particularly around the time of diagnosis and treatment and with advanced disease. While many cancer survivors continue with paid work, participation is reduced. Workforce retention support should be tailored to survivor preferences, cancer type and cancer journey stage.
Identifiants
pubmed: 34008147
doi: 10.1007/s11764-021-01041-7
pii: 10.1007/s11764-021-01041-7
pmc: PMC8964624
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
461-473Subventions
Organisme : National Health and Medical Research Council
ID : 1139539
Informations de copyright
© 2021. The Author(s).
Références
Support Care Cancer. 2014 Jan;22(1):181-7
pubmed: 24026981
Int J Epidemiol. 2008 Oct;37(5):941-7
pubmed: 17881411
J Health Econ. 2018 Mar;58:151-175
pubmed: 29486331
J Cancer Surviv. 2008 Mar;2(1):20-32
pubmed: 18648984
J Cancer Surviv. 2017 Aug;11(4):453-461
pubmed: 28213769
BMC Med Res Methodol. 2010 Apr 01;10:26
pubmed: 20356408
Occup Med (Lond). 2019 Apr 13;69(2):126-132
pubmed: 30882861
Eur J Cancer Care (Engl). 2017 Sep;26(5):
pubmed: 28771857
Med Care. 2007 May;45(5 Suppl 1):S32-8
pubmed: 17443117
J Health Econ. 2011 May;30(3):505-14
pubmed: 21429606
Support Care Cancer. 2007 May;15(5):515-23
pubmed: 17120068
Health Econ. 2017 May;26(5):671-684
pubmed: 27045223
J Cancer Surviv. 2015 Jun;9(2):349-60
pubmed: 25492237
Cancer. 2015 Mar 1;121(5):758-65
pubmed: 25369293
Eur J Public Health. 2013 Feb;23(1):116-22
pubmed: 22227027
J Thorac Oncol. 2012 Jan;7(1):64-70
pubmed: 22134070
Support Care Cancer. 2012 Sep;20(9):1957-64
pubmed: 22033835
J Cancer Surviv. 2020 Apr;14(2):114-134
pubmed: 31858379
Chron Respir Dis. 2012 Feb;9(1):39-47
pubmed: 22308553
Int J Epidemiol. 2013 Aug;42(4):1012-4
pubmed: 24062287
Psychooncology. 2005 Mar;14(3):221-6
pubmed: 15386773
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
PLoS One. 2009;4(1):e4191
pubmed: 19142227
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795
Psychooncology. 2017 Sep;26(9):1354-1360
pubmed: 27862573